TGFB1 and melanoma: GC1008 (fresolimumab), a human anti-TGF−β monoclonal antibody, has been tested in patients with advanced malignant melanoma, renal cell carcinoma, and diabetic nephropathy and demonstrated acceptable safety and preliminary evidence of antitumor activity (37, 38).